Trevena (NASDAQ:TRVN) Earns Neutral Rating from HC Wainwright

HC Wainwright reissued their neutral rating on shares of Trevena (NASDAQ:TRVN) in a report released on Thursday, Marketbeat Ratings reports. The brokerage currently has a $5.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Trevena’s Q1 2025 earnings at ($0.37) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.37) EPS and Q4 2025 earnings at $0.18 EPS.

Separately, StockNews.com initiated coverage on Trevena in a report on Monday. They issued a “sell” rating for the company.

Trevena Trading Up 4.7 %

NASDAQ:TRVN traded up $0.08 on Thursday, reaching $1.77. 883 shares of the stock traded hands, compared to its average volume of 25,869. The firm has a market capitalization of $1.52 million, a price-to-earnings ratio of -0.04 and a beta of 1.08. Trevena has a 1-year low of $1.13 and a 1-year high of $19.23. The company’s 50 day moving average is $3.15 and its 200-day moving average is $5.72.

Trevena (NASDAQ:TRVN) last issued its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share (EPS) for the quarter. The company had revenue of $0.28 million during the quarter. On average, equities research analysts forecast that Trevena will post -32.25 EPS for the current fiscal year.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.